• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Renal impairment in monoclonal gammopathies and multiple myeloma

by | Jul 10, 2024 | Publications

Cas Lek Cesk. 2024;163(3):98-105. ABSTRACT The incidence of monoclonal gammopathy (MG) increases with age. In individuals over 80 years of age, we can diagnose the presence of monoclonal immunoglobulin (MIg) in up to 10 % of cases. Not only malignant diseases such as...

The comparative efficacy and safety of factor Xa inhibitors and warfarin for primary thromboprophylaxis in multiple myeloma patients undergoing immunomodulatory therapy

by | Jul 10, 2024 | Publications

Br J Haematol. 2024 Jun 21. doi: 10.1111/bjh.19612. Online ahead of print. ABSTRACT There are limited data on the optimal choice of anticoagulation in multiple myeloma (MM) patients receiving immunomodulatory drugs (IMiDs). We conducted a propensity score-matched...

Leukocyte immunoglobulin-like receptor B1 (LILRB1) protects human multiple myeloma cells from ferroptosis by maintaining cholesterol homeostasis

by | Jul 10, 2024 | Publications

Nat Commun. 2024 Jul 9;15(1):5767. doi: 10.1038/s41467-024-50073-x. ABSTRACT Multiple myeloma (MM) is a hematologic malignancy characterized by uncontrolled proliferation of plasma cells in the bone marrow. MM patients with aggressive progression have poor survival,...

Risk of infections with bispecific antibodies in B-cell non-Hodgkin lymphomas and multiple myeloma-The current state

by | Jul 10, 2024 | Publications

Br J Haematol. 2024 Jul 9. doi: 10.1111/bjh.19633. Online ahead of print. NO ABSTRACT PMID:38981510 | DOI:10.1111/bjh.19633

Understanding CAR-T therapy in myeloma: 1 cell at a time

by | Jul 9, 2024 | Publications

Blood Adv. 2024 Jul 9;8(13):3560-3561. doi: 10.1182/bloodadvances.2024013292. NO ABSTRACT PMID:38980672 | DOI:10.1182/bloodadvances.2024013292

LINC01432 binds to CELF2 in newly diagnosed multiple myeloma promoting short progression-free survival to standard therapy

by | Jul 9, 2024 | Publications

bioRxiv [Preprint]. 2024 Jun 30:2024.06.27.600975. doi: 10.1101/2024.06.27.600975. ABSTRACT Multiple Myeloma (MM) is a highly prevalent and incurable form of cancer that arises from malignant plasma cells, with over 35,000 new cases diagnosed annually in the United...
« Older Entries
Next Entries »

Recent Content

  • FDA Update: Darzalex Faspro Not Approved for Multiple Myeloma
  • Temporal genomic dynamics shape clinical trajectory in multiple myeloma
  • Bone Marrow Microenvironments Vary Widely in Multiple Myeloma, Study Finds
  • Safety and efficacy of BCMA CAR-T vs. bispecific antibodies in patients with relapsed multiple myeloma: a systematic review and meta-analysis
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
  • Why New Patients With Multiple Myeloma ‘Can Expect Long, Healthy Lives’
  • Future Perspectives in Multiple Myeloma
  • Patients and Caregivers Aim to Raise Funds for Myeloma Research
  • GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series
  • Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial data
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT